Autologous Serum Eye Drops for Post-Chemical Injuries and Corneal Epithelial Defects

Authors

  • Mirjana A. Janicijevic-Petrovic Clinic of Ophthalmology, Clinical Centre of Kragujevac, Kragujevac
  • Marko Petrovic Faculty of Medical Sciences, University of Kragujevac, Kragujevac
  • Dragan Vujic Faculty of Medical Sciences, University of Kragujevac, Kragujevac
  • Katarina Janicijevic Faculty of Medical Sciences, University of Kragujevac, Kragujevac
  • Andrijana Popovic Faculty of Medical Sciences, University of Kragujevac, Kragujevac

DOI:

https://doi.org/10.3889/oamjms.2013.009

Keywords:

autologous serum, eye drops, chemical injuries, corneal defects, treatment.

Abstract

Aim: To evaluate success rate (efficacy, safety) in treatment of post-chemical injuries and corneal defects using autologous serum eye drops.

Material and Methods: Authors reviewed 93 patients (116 eyes) hospitalized in Clinic of ophthalmology from 2010 to 2013, who had post-causoma corneal defects that were nonresponsive to conventional treatment and were treated with serum therapy. Authors correlated time of epithelialization of defects with rate of epithelial healing.

Results: Authors investigated 93 patients (52 males, 41 females; aged 18 - 74) for treatment of corneal defects. Application of autologous serum therapy 56 (48.28%) of 116 eyes was healed in an average time of 4 weeks. Among 116 eyes, epithelial defects healed in 4 (3.45%) within 1 week, in additional 17 (14.65%) in 1-2 weeks, totalling 31 (26.72%) within 3 weeks. Five eyes (4.31%) completely healed at 5 week; three eyes (2.59%) had subsequent healing of epithelial defect at 6 week; 56 eyes completely healed within one month, and the remaining eight eyes healed within 1.5 month.

Conclusion: Using serum therapy, it was managed to reduce time of healing from eleven weeks, which were necessary just couple years ago (before 2010) to four (maximum six) weeks to complete healing which are necessary today.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Geerling G, Hartwig D. Autologous serum eye drops for ocular surface disorders. A literature review and recommendations for their application. Ophthalmologe. 2002; 99(12):949-59.

López-García JS, García-Lozano I, Rivas L, Martínez-Garchitorena J. Use of autologous serum in ophthalmic practice. Arch Soc Esp Oftalmol. 2007; 82(1):9-20.

Jeng BH, Dupps WJ Jr. Autologous serum 50% eye drops in the treatment of persistent corneal epithelial defects. Cornea. 2009; 28(10):1104-8.

Chiang CC, Chen WL, Lin JM, Tsai YY. Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect. Eye (Lond). 2009; 23(2):290-3.

Kim KM, Shin YT, Kim HK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol. 2012; 56(6):544-50.

Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eye drops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001; 85(10):1188-97.

Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M, Tsubota K. The effect of autologous serum eye drops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol. 2005; 139(2):242-6.

López-García JS, Rivas L, García-Lozano I, Murube J. Autologous serum eye drops in the treatment of aniridic keratopathy. Ophthalmology. 2008; 115(2):262-7.

Wilczyński M. The use of autologous serum in the treatment of the ocular surface diseases. Klin Oczna. 2009; 111(10-12):363-8.

Nishida T. The cornea: stasis and dynamics. Nihon Ganka Gakkai Zasshi. 2008; 112(3):179-212.

Alvarado Valero MC, Martínez Toldos JJ, Borras Blasco J, Almiñana Almiñana A, Pérez Ramos JM. Treatment of persistent epithelial defects using autologous serum application. Arch Soc Esp Oftalmol. 2004; 79(11):537-42.

Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999; 106(10):1984-9.

Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001; 20(8):807-10.

Phan TM, Foster CS, Shaw CD, Zagachin LM, Colvin RB. Topical fibronectin in an alkali burn model of corneal ulceration in rabbits. Arch Ophthalmol. 1991; 109(3):414-9.

Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Geerling G. An optimised protocol for the production of autologous serum eye drops. Graefes Arch Clin Exp Ophthalmol. 2005; 243(7):706-14.

García Jiménez V, Veiga Villaverde B, Baamonde Arbaiza B, Cahue Carpintero I, Celemín Viñuela ML, Simó Martínez RM. The elaboration, use and evaluation of eye-drops with autologous serum in corneal lesions. Farm Hosp. 2003; 27(1):21-5.

Sauer R, Blüthner K, Seitz B. Sterility of non-preserved autologous serum drops for treatment of persistent corneal epithelial defects. Ophthalmologe. 2004; 101(7):705-9.

Downloads

Published

2013-12-15

How to Cite

1.
Janicijevic-Petrovic MA, Petrovic M, Vujic D, Janicijevic K, Popovic A. Autologous Serum Eye Drops for Post-Chemical Injuries and Corneal Epithelial Defects. Open Access Maced J Med Sci [Internet]. 2013 Dec. 15 [cited 2021 Apr. 16];1(1):45-9. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2013.009

Issue

Section

B - Clinical Sciences

Most read articles by the same author(s)